v3.26.1
Intangible assets
12 Months Ended
Dec. 31, 2025
Intangible assets  
Intangible assets

8. Intangible assets

 

Cost

 

Licenses

 

 

Patents and drug approvals

 

 

Brand names and trademarks

 

 

Customer list

 

 

Software and technology

 

 

Total

 

At December 31, 2023

 

$1,227

 

 

$25,386

 

 

$4,746

 

 

$5,787

 

 

$1,031

 

 

$38,177

 

Additions

 

 

-

 

 

 

100

 

 

 

-

 

 

 

-

 

 

 

639

 

 

 

739

 

Transfer from prepaid expenses

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

795

 

 

 

795

 

Effect of movements in exchange rates

 

 

107

 

 

 

2,238

 

 

 

417

 

 

 

509

 

 

 

147

 

 

 

3,418

 

At December 31, 2024

 

$1,334

 

 

$27,724

 

 

$5,163

 

 

$6,296

 

 

$2,612

 

 

$43,129

 

Additions - business combinations (note 4)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

954

 

 

 

-

 

 

 

954

 

Effect of movements in exchange rates

 

 

(58)

 

 

(1,316)

 

 

(245)

 

 

(305)

 

 

(125)

 

 

(2,049)

At December 31, 2025

 

$1,276

 

 

$26,408

 

 

$4,918

 

 

$6,945

 

 

$2,487

 

 

$42,034

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated amortization

 

Licenses

 

 

Patents and drug approvals

 

 

Brand names and trademarks

 

 

Customer list

 

 

Software and technology

 

 

Total

 

At December 31, 2023

 

$532

 

 

$21,147

 

 

$4,388

 

 

$2,937

 

 

$233

 

 

$29,237

 

Amortization

 

 

182

 

 

 

620

 

 

 

53

 

 

 

746

 

 

 

275

 

 

 

1,876

 

Effect of movements in exchange rates

 

 

56

 

 

 

1,890

 

 

 

389

 

 

 

296

 

 

 

31

 

 

 

2,662

 

At December 31, 2024

 

$770

 

 

$23,657

 

 

$4,830

 

 

$3,979

 

 

$539

 

 

$33,775

 

Amortization

 

 

185

 

 

 

633

 

 

 

54

 

 

 

845

 

 

 

435

 

 

 

2,152

 

Effect of movements in exchange rates

 

 

(40)

 

 

(1,132)

 

 

(230)

 

 

(205)

 

 

(34)

 

 

(1,641)

At December 31, 2025

 

$915

 

 

$23,158

 

 

$4,654

 

 

$4,619

 

 

$940

 

 

$34,286

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Carrying amounts

 

Licenses

 

 

Patents and drug approvals

 

 

Brand names and trademarks

 

 

Customer list

 

 

Software and technology

 

 

Total

 

At December 31, 2024

 

$564

 

 

$4,067

 

 

$333

 

 

$2,317

 

 

$2,073

 

 

$9,354

 

At December 31, 2025

 

$361

 

 

$3,250

 

 

$264

 

 

$2,326

 

 

$1,547

 

 

$7,748

 

 

The Company had determined there were no indicators of impairment as at December 31, 2025 or December 31, 2024. 

 

Intangible assets pertaining to the AGGRASTAT® patent were fully amortized.

 

During the year ended December 31, 2024, the Company reclassified $795 from prepaid expenses to intangible assets in connection with the successful implementation of a technology transfer to its contracted manufacturing organization. This transfer enabled the production of the Company’s AGGRASTAT® bolus vial at the contracted manufacturing facility. Following this achievement, the Company commenced commercialization of the product manufactured at the new facility during the current year. The Company has elected to amortize this asset over a period of 7 years, with 5.75 years remaining as at December 31, 2025.

 

For the year ended December 31, 2025, amortization of intangible assets totaling $633 (2024 - $620 and 2023 - $611) is recorded within cost of goods sold pertaining to the ZYPITAMAG® intangible assets. In addition, for the year ended December 31, 2025, $1,519 (2024 - $1,269 and 2023 – $1,125) of amortization of intangible assets is recorded within selling expenses as a result of the amortization of the intangible assets pertaining to Marley Drug, Gateway Pharmacy and West Olympia Pharmacy.